Redmile Group, LLC Stoke Therapeutics, Inc. Transaction History

Redmile Group, LLC

$822 Million
Q2 2025

A detailed history of Redmile Group, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,375,931 shares of STOK stock, worth $139 Million. This represents 6.04% of its overall portfolio holdings.

Number of Shares

4,375,931

Previous 4,485,981 2.45%

Holding current value

$139 Million

Previous $29.8 Million 66.49%

% of portfolio

6.04%

Previous 3.13%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$5.9 - $11.84 $649,295 - $1.3 Million	-110,050 Reduced 2.45%	4,375,931 $49.7 Million
Q1 2025 May 15, 2025	SELL	$6.65 - $12.74 $715,859 - $1.37 Million	-107,648 Reduced 2.34%	4,485,981 $29.8 Million
Q4 2024 Feb 14, 2025	SELL	$10.8 - $13.92 $1.29 Million - $1.67 Million	-119,880 Reduced 2.54%	4,593,629 $50.7 Million
Q3 2024 Nov 14, 2024	SELL	$12.24 - $15.92 $92,350 - $120,116	-7,545 Reduced 0.16%	4,713,509 $57.9 Million
Q2 2024 Aug 14, 2024	SELL	$11.03 - $17.52 $3.88 Million - $6.17 Million	-351,995 Reduced 6.94%	4,721,054 $63.8 Million
Q1 2024 May 15, 2024	BUY	$4.12 - $14.17 $10.1 Million - $34.7 Million	2,447,543 Added 93.22%	5,073,049 $68.5 Million
Q4 2023 Feb 14, 2024	SELL	$3.37 - $5.4 $4.48 Million - $7.18 Million	-1,329,682 Reduced 33.62%	2,625,506 $13.8 Million
Q2 2023 Aug 14, 2023	SELL	$7.93 - $13.82 $1.51 Million - $2.63 Million	-190,208 Reduced 4.59%	3,955,188 $42 Million
Q1 2023 May 15, 2023	BUY	$7.65 - $10.38 $26.8 Million - $36.4 Million	3,502,966 Added 545.27%	4,145,396 $34.5 Million
Q4 2022 Feb 14, 2023	SELL	$7.07 - $15.69 $1.37 Million - $3.03 Million	-193,400 Reduced 23.14%	642,430 $5.93 Million
Q3 2022 Nov 14, 2022	SELL	$12.56 - $22.53 $14.5 Million - $26.1 Million	-1,157,438 Reduced 58.07%	835,830 $10.7 Million
Q2 2022 Aug 15, 2022	SELL	$10.36 - $23.93 $322,196 - $744,223	-31,100 Reduced 1.54%	1,993,268 $26.3 Million
Q1 2022 May 16, 2022	SELL	$17.19 - $26.1 $3.82 Million - $5.8 Million	-222,300 Reduced 9.89%	2,024,368 $42.6 Million
Q4 2021 Feb 14, 2022	SELL	$18.11 - $30.72 $2.45 Million - $4.16 Million	-135,290 Reduced 5.68%	2,246,668 $53.9 Million
Q3 2021 Nov 15, 2021	SELL	$23.65 - $34.44 $1.81 Million - $2.64 Million	-76,600 Reduced 3.12%	2,381,958 $60.6 Million
Q2 2021 Aug 16, 2021	SELL	$30.53 - $41.09 $2.61 Million - $3.51 Million	-85,504 Reduced 3.36%	2,458,558 $82.8 Million
Q1 2021 May 17, 2021	SELL	$36.08 - $69.81 $5.13 Million - $9.93 Million	-142,172 Reduced 5.29%	2,544,062 $98.8 Million
Q4 2020 Feb 16, 2021	BUY	$33.62 - $61.93 $4.6 Million - $8.47 Million	136,728 Added 5.36%	2,686,234 $166 Million
Q3 2020 Nov 16, 2020	BUY	$22.23 - $37.48 $1.05 Million - $1.77 Million	47,200 Added 1.89%	2,549,506 $85.4 Million
Q2 2020 Aug 14, 2020	BUY	$20.26 - $29.73 $6.81 Million - $10 Million	336,368 Added 15.53%	2,502,306 $59.6 Million
Q1 2020 May 15, 2020	BUY	$16.8 - $34.15 $19.2 Million - $39.1 Million	1,145,160 Added 112.19%	2,165,938 $49.6 Million
Q4 2019 Feb 14, 2020	BUY	$20.01 - $30.79 $66,033 - $101,607	3,300 Added 0.32%	1,020,778 $28.9 Million
Q3 2019 Nov 14, 2019	SELL	$20.53 - $37.72 $88,894 - $163,327	-4,330 Reduced 0.42%	1,017,478 $21.9 Million
Q2 2019 Aug 14, 2019	BUY	$25.53 - $29.17 $26.1 Million - $29.8 Million	1,021,808 New	1,021,808 $29.8 Million

Others Institutions Holding STOK

# of Institutions

144

Shares Held

57M

Call Options Held

2.7K

Put Options Held

57.4K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $1.25B
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Stoke Therapeutics, Inc. Transaction History